(NASDAQ: CDXC) Chromadex's forecast annual revenue growth rate of 18.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.05%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.25%.
Chromadex's revenue in 2024 is $83,167,000.On average, 2 Wall Street analysts forecast CDXC's revenue for 2024 to be $7,348,035,505, with the lowest CDXC revenue forecast at $7,338,593,157, and the highest CDXC revenue forecast at $7,357,477,854. On average, 2 Wall Street analysts forecast CDXC's revenue for 2025 to be $8,713,399,080, with the lowest CDXC revenue forecast at $8,686,960,505, and the highest CDXC revenue forecast at $8,739,837,656.
In 2026, CDXC is forecast to generate $10,341,259,940 in revenue, with the lowest revenue forecast at $10,341,259,940 and the highest revenue forecast at $10,341,259,940.